-
1دورية أكاديمية
المؤلفون: Sanchini, Virginia, Devriendt, Thijs, Borry, Pascal
المساهمون: V. Sanchini, T. Devriendt, P. Borry
مصطلحات موضوعية: Anti-doping research, CIOMS Guideline, Helsinki Declaration, bioethic, research ethic, Antineoplastic Protocol, Biomedical Research, Doping in Sport, Human, Laboratorie, Organizational Objective, Risk Assessment, Vulnerable Population, International Cooperation, Settore M-FIL/03 - Filosofia Morale, Settore MED/02 - Storia della Medicina
الوصف: The fight against doping in sport is internationally coordinated by the World Anti-Doping Agency (WADA). Through its World Anti-Doping Code, WADA aims to harmonize anti-doping policies, rules and regulations. One key reference document bound to the Code is the International Standard for Laboratories (ISL), which mainly specifies the criteria that must be met for laboratory accreditation, as well as standards to adopt for the production of valid test results and evidentiary data. Within the ISL, the Code of Ethics refers to the Helsinki Declaration as a guiding framework for anti-doping research. However, inasmuch as anti-doping research structurally differs from human subject research as considered by the Helsinki Declaration, the applicability of the latter to anti-doping research can be called into question. In this work, we discuss how key principles of the Helsinki Declaration apply to anti-doping research and highlight frictions, incompatibilities and misalignments. Furthermore, we indicate possible solutions for operationalizing the Helsinki principles within the context of anti-doping research.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32088983; info:eu-repo/semantics/altIdentifier/wos/WOS:000524239100001; volume:27; issue:4; firstpage:179; lastpage:194; numberofpages:16; journal:ACCOUNTABILITY IN RESEARCH; http://hdl.handle.net/2434/938295Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85083378399
-
2دورية أكاديمية
المؤلفون: Arslan C., Atilla F.D.
مصطلحات موضوعية: Advanced gastric cancer, Capecitabine maintenance, Modified DCF, Treatment, capecitabine, cisplatin, docetaxel, fluorouracil, folinic acid, granulocyte colony stimulating factor, irinotecan, antineoplastic agent, taxoid, adult, aged, anemia, antineoplastic protocol, Article, cancer combination chemotherapy, cancer patient, cancer survival, carcinomatous peritonitis, case report, chemotherapy induced nausea and vomiting, clinical article, comparative effectiveness, death, disease free interval, drug dose reduction, drug efficacy
الوصف: Background: Little progress has been made, and there is an unmet medical need for treatment of metastatic gastric cancer (MGC). Docetaxel + cisplatin + 5-fluororacil (DCF) combination is an effective regimen with high rate of toxicity and is not well tolerated. We aimed to evaluate the efficacy and toxicity of a modified DCF (mDCF) combination regimen and capecitabine maintenance in MGC. Method: Data of MGC patients were treated with first-line mDCF regimen (two weekly docetaxel 60 mg/m2 day 1 iv, cisplatin 50 mg/m2 day 1 iv, 5-fluouracil 400 mg/m2 day 1 iv push, 2400 mg/m2; day 1–day 2 iv infusion, leucovorin 400 mg/m2 day 1 iv push) were recorded. Capecitabine maintenance was given as 2500 mg/m2/ day 1–day 14 po, every 3 weeks, to patients who do not have progressive disease and grade 3 treatment-related toxicity. A retrospective analysis was made. Results: Forty patients were included. Mean age was 53 ± 11. Thirty-two patients had de novo metastasis. All patients’ performance status was ECOG 1 or 2 (32/8). Median number of mDCF cycles given was 9 (min–max: 1–23). Overall response rate was 47.5%. Ten patients (25%) received capecitabine maintenance. Grade 3/4 toxicity was seen in 20 patients (50%). Hematologic grade 3/4 toxicity occurred in 13 patients (32.5%), and grade 3/4 neutropenia occurred in 11 patients (27.5%) and in 15 cycles. Nonhematologic grade 3/4 toxicity was seen in 7 patients (17.5%). Median follow-up time was 17.2 months. Median time to progression (TTP) was 10.8 ± 1.9 months (95% CI: 6.89–14.64). Median overall survival was 14.7 ± 1.73 months (95% CI: 11.30–18.10). Conclusions: mDCF protocol was a tolerable chemotherapy regimen for the first-line treatment of MGC with higher ORR and longer TTP compared to standard DCF protocol. Capecitabine maintenance might increase TTP. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
العلاقة: Supportive Care in Cancer; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1007/s00520-022-06859-0Test; https://hdl.handle.net/20.500.14034/849Test; 30; 4447; 4455; 2-s2.0-85124095241
الإتاحة: https://doi.org/20.500.14034/849Test
https://doi.org/10.1007/s00520-022-06859-0Test
https://hdl.handle.net/20.500.14034/849Test -
3
المؤلفون: Aiwu Ruth He, Robin Kate Kelley, Ahmed Kaseb, David J. Pinato, Lipika Goyal, Amaia Lujambio, Bruno Sangro, Peter R. Galle, Ignacio Melero, Ghassan K. Abou-Alfa, Austin G. Duffy, Roberto I. Troisi, Riccardo Lencioni, Andrew X. Zhu, Anthony B. El-Khoueiry, Ann-Lii Cheng, Tim F. Greten, Richard S. Finn, Donna Mabry Hrones, Andrea Wilson Woods, Thomas Yau
المساهمون: Greten, T. F., Abou-Alfa, G. K., Cheng, A. -L., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., Kelley, R. K., Lencioni, R., Lujambio, A., Mabry Hrones, D., Pinato, D. J., Sangro, B., Troisi, R., Wilson Woods, A., Yau, T., Zhu, A. X., Melero, I.
المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, antineoplastic protocols, guidelines as topic, immunotherapy, liver neoplasms, Bevacizumab, medicine.medical_treatment, Immunology, Guidelines as Topic, Disease, Quality of life (healthcare), Atezolizumab, Internal medicine, liver neoplasm, medicine, Immunology and Allergy, Humans, Radiation treatment planning, RC254-282, Pharmacology, business.industry, Liver Neoplasms, Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Guideline, Immunotherapy, medicine.disease, antineoplastic protocol, Molecular Medicine, business, Human, medicine.drug
الوصف: Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985f6c1cc594fe44c600e74a9246e674Test
https://pubmed.ncbi.nlm.nih.gov/34518290Test -
4دورية أكاديمية
المؤلفون: Passiglia F., Bertaglia V., Reale M. L., Delcuratolo M. D., Tabbo F., Olmetto E., Capelletto E., Bironzo P., Novello S.
المساهمون: Passiglia F., Bertaglia V., Reale M.L., Delcuratolo M.D., Tabbo F., Olmetto E., Capelletto E., Bironzo P., Novello S.
مصطلحات موضوعية: Adjuvant Treatment, Chemotherapy, Early stage, Immunotherapy, Non-small cell lung cancer, Radiotherapy, Targeted therapy, Antineoplastic Protocol, Clinical Trials as Topic, Combined Modality Therapy, Human, Immune Checkpoint Inhibitor, Neoplasm Staging, Carcinoma, Non-Small-Cell Lung, Adjuvant, Lung Neoplasms
الوصف: We are witnessing a silent revolution in the treatment of early stage non-small cell lung cancer (NSCLC), with a series of practice-changing clinical trials enriching the therapeutic perspectives of lung cancer patients with potentially curable disease. The ADAURA study marked the advent of precision medicine and biomarker testing to the early stages setting. The IMPower-010 trial interrupted the negative trend of adjuvant lung cancer immunotherapy, paving the way to the application of immune-checkpoint inhibition in the resected disease. The ITACA trial definitively established no role for tailored adjuvant chemotherapy in NSCLC, while the Lung Art data questioned the efficacy of post-operative radiotherapy for pN2 resected disease. Growing evidence is supporting MRD as effective adjuvant prognostic biomarker to stratify disease's recurrence risk after radical interventions and select best candidates to the adjuvant strategies. This work summarizes the recent major breakthroughs in lung cancer adjuvant treatment, and provides a snapshot of the current real-world scenario, discussing the upcoming challenges and opportunities featuring the clinical management of early stage NSCLC patients.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34757306; info:eu-repo/semantics/altIdentifier/wos/WOS:000722417700001; volume:101; firstpage:102308; lastpage:102315; numberofpages:8; journal:CANCER TREATMENT REVIEWS; http://hdl.handle.net/2318/1835503Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118339628
-
5دورية أكاديمية
المؤلفون: Kyriazoglou A., Bagos P.
المصدر: Acta Oncologica ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101618671&doi=10.1080%2f0284186X.2021.1890818&partnerID=40&md5=528314669d782da7bb86d49c1522718bTest
مصطلحات موضوعية: antineoplastic agent, cisplatin, cyclophosphamide, dactinomycin, doxorubicin, epirubicin, ifosfamide, methotrexate, nedaplastin, unclassified drug, vincristine, BCOR protein, human, oncoprotein, repressor protein, tumor marker, adolescent, aged, antineoplastic protocol, Article, BCOR rearranged sarcoma, bone cancer, cancer chemotherapy, cancer genetics, cancer localization, cancer mortality, cancer radiotherapy, cancer staging, cancer surgery, cancer survival
الوصف: Introduction: BCOR rearranged sarcomas comprise a group of malignant mesenchymal tumors that until recently were classified as Ewing sarcomas or as undifferentiated round cell sarcomas. The identification of alterations involving BCOR gene such as BCOR-CCNB3, BCOR-MAML3, ZC3H7B-BCOR fusion genes and BCOR internal tandem duplication (ITD) is characteristic for the differential diagnosis of BCOR rearranged sarcomas. Due to the rarity of these tumors there is no consensus or guidelines regarding the optimal therapeutic algorithm, that clinicians should follow. Patients and methods: Herein we have conducted a meta-analysis of the current reports dealing with the therapeutic approach of BCOR rearranged sarcomas. Results: Meta-analysis of the 57 eligible cases from 10 studies resulted to similar Incidence Rate Ratio (IRR) and overall survival (OS) for patients who received Ewing protocols and non-Ewing oriented treatment. Further similar death rate was reported for both strategies (non-Ewing 20% Vs Ewing 21.8%). Conclusion: Our data support that non-Ewing treatment strategy can be considered a safe option, being at least equal to Ewing protocols. The current study provides a hint toward the optimal therapeutic approach of BCOR rearranged sarcomas. Further, the present study challenges the use of the term Ewing-like sarcomas, since the current literature supports that BCOR rearranged sarcomas deserve their own distinct classification in terms of genetics, pathology and therapy. © 2021 Acta Oncologica Foundation.
-
6دورية أكاديمية
المؤلفون: Greten T. F., Abou-Alfa G. K., Cheng A. -L., Duffy A. G., El-Khoueiry A. B., Finn R. S., Galle P. R., Goyal L., He A. R., Kaseb A. O., Kelley R. K., Lencioni R., Lujambio A., Mabry Hrones D., Pinato D. J., Sangro B., Troisi R. I., Wilson Woods A., Yau T., Zhu A. X., Melero I.
المساهمون: Greten, T. F., Abou-Alfa, G. K., Cheng, A. -L., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., Kelley, R. K., Lencioni, R., Lujambio, A., Mabry Hrones, D., Pinato, D. J., Sangro, B., Troisi, R. I., Wilson Woods, A., Yau, T., Zhu, A. X., Melero, I.
مصطلحات موضوعية: antineoplastic protocol, guidelines as topic, immunotherapy, liver neoplasms
الوصف: Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34518290; info:eu-repo/semantics/altIdentifier/wos/WOS:000697845700001; volume:9; issue:9; firstpage:e002794; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; https://hdl.handle.net/11568/1113401Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85115015817
-
7دورية أكاديمية
المؤلفون: Ottaviano M., Curvietto M., Rescigno P., Tortora M., Palmieri G., Giannarelli D., Aieta M., Assalone P., Attademo L., Avallone A., Bloise F., Bosso D., Borzillo V., Buono G., Calderoni G., Caputo F., Carteni G., Cavallero D., Cavo A., Ciardiello F., Conca R., Conteduca V., De Falco S., De Felice M., De Laurentiis M., De Placido P., De Placido S., De Santo I., De Stefano A., Della Corte C. M., Di Franco R., Di Lauro V., Fabbrocini A., Federico P., Festino L., Giordano P., Giuliano M., Gridelli C., Grimaldi A. M., Lia M., Marretta A. L., Massa V., Mennitto A., Merler S., Merz V., Messina C., Messina M., Milano M., Minisini A. M., Montesarchio V., Morabito A., Morgillo F., Mucci B., Nappi L., Napolitano F., Paciolla I., Pagliuca M., Parola S., Pepe S., Petrillo A., Piantedosi F., Piccin L., Picozzi F., Pietroluongo E., Pignata S., Prati V., Riccio V., Rosanova M., Rossi A., Russo A., Salati M., Santabarbara G., Sbrana A., Simeone E., Silvestri A., Spada M., Tarantino P., Taveggia P., Tomei F., Vincenzo T., Trapani D., Trojanello C., Vanella V., Vari S., Ventriglia J., Vitale M. G., Vitiello F., Vivaldi C., Von Arx C., Zacchi F., Zampiva I., Zivi A., Daniele B., Ascierto P. A.
المساهمون: Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.
مصطلحات موضوعية: antineoplastic protocol, healthcare economics and organization, immunotherapy, lung neoplasm, melanoma, Adult, Antineoplastic Agents, Immunological, B7-H1 Antigen, Betacoronaviru, COVID-19, CTLA-4 Antigen, Coronavirus Infection, Drug Prescription, Female, Geography, Human, Infection Control, Italy, Male, Medical Oncology, Neoplasm, Oncologist, Pandemic, Pneumonia, Viral, Practice Patterns, Physicians', Prevalence, Programmed Cell Death 1 Receptor
الوصف: Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33060148; info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; volume:8; firstpage:e001154; lastpage:e001154; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11386/4756291Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336
-
8
المؤلفون: Sara Parola, Diletta Cavallero, Pietro De Placido, Rossella Di Franco, Francesca Zacchi, Giacomo Cartenì, Sabino De Placido, Claudia von Arx, Alice Rossi, Fernanda Picozzi, Pasquale Rescigno, Laura Attademo, Giovannella Palmieri, Carminia Maria Della Corte, Fabiana Vitiello, Anna Russo, Lucia Nappi, Michele Aieta, Alessia Mennitto, Fabiana Napolitano, Marco Messina, Giuseppe Buono, Valeria Merz, Marco De Felice, Stefano De Falco, Immacolata Paciolla, Irene De Santo, Dario Trapani, Antonio M. Grimaldi, Paolo Tarantino, Alessandro Morabito, Tortora Vincenzo, Stefano Pepe, Giuseppe Palmieri, Antonietta Fabbrocini, Diana Giannarelli, Alfonso De Stefano, Sabrina Vari, Cesare Gridelli, Vittorio Riccio, Angelica Petrillo, Martina Pagliuca, Giuseppe Calderoni, Margaret Ottaviano, Vincenza Conteduca, Michela Lia, Giuseppe Santabarbara, Ester Simeone, Valentina Borzillo, Francesca Caputo, Mario Rosanova, Marcello Curvietto, Pasquale Assalone, Brigitta Mucci, Raffaele Conca, Vito Vanella, Francovito Piantedosi, Vincenzo Montesarchio, Erica Pietroluongo, Lucia Festino, Federica Tomei, Vincenzo Di Lauro, Bruno Daniele, Caterina Vivaldi, Andrea Zivi, Veronica Prati, Pasqualina Giordano, Luisa Piccin, Francesco Bloise, Massimiliano Spada, Jole Ventriglia, Davide Bosso, Alessandro Marco Minisini, Massimiliano Salati, Monica Milano, Carlo Messina, Valentina Massa, Mario Giuliano, Claudia Trojanello, Antonella Lucia Marretta, Fortunato Ciardiello, Antonio Avallone, Marianna Tortora, Ilaria Zampiva, Alessia Cavo, Floriana Morgillo, Andrea Sbrana, Piera Federico, Maria Grazia Vitale, Sandro Pignata, Antonia Silvestri, Paola Taveggia, Sara Merler, Paolo A. Ascierto, Michelino De Laurentiis
المساهمون: Ottaviano, Margaret, Curvietto, Marcello, Rescigno, Pasquale, Tortora, Marianna, Palmieri, Giovannella, Giannarelli, Diana, Aieta, Michele, Assalone, Pasquale, Attademo, Laura, Avallone, Antonio, Bloise, Francesco, Bosso, Davide, Borzillo, Valentina, Buono, Giuseppe, Calderoni, Giuseppe, Caputo, Francesca, Cartenì, Giacomo, Cavallero, Diletta, Cavo, Alessia, Ciardiello, Fortunato, Conca, Raffaele, Conteduca, Vincenza, De Falco, Stefano, De Felice, Marco, De Laurentiis, Michelino, De Placido, Pietro, De Placido, Sabino, De Santo, Irene, De Stefano, Alfonso, Della Corte, Carminia Maria, Di Franco, Rossella, Di Lauro, Vincenzo, Fabbrocini, Antonietta, Federico, Piera, Festino, Lucia, Giordano, Pasqualina, Giuliano, Mario, Gridelli, Cesare, Grimaldi, Antonio Maria, Lia, Michela, Marretta, Antonella Lucia, Massa, Valentina, Mennitto, Alessia, Merler, Sara, Merz, Valeria, Messina, Carlo, Messina, Marco, Milano, Monica, Minisini, Alessandro Marco, Montesarchio, Vincenzo, Morabito, Alessandro, Morgillo, Floriana, Mucci, Brigitta, Nappi, Lucia, Napolitano, Fabiana, Paciolla, Immacolata, Pagliuca, Martina, Palmieri, Giuseppe, Parola, Sara, Pepe, Stefano, Petrillo, Angelica, Piantedosi, Francovito, Piccin, Luisa, Picozzi, Fernanda, Pietroluongo, Erica, Pignata, Sandro, Prati, Veronica, Riccio, Vittorio, Rosanova, Mario, Rossi, Alice, Russo, Anna, Salati, Massimiliano, Santabarbara, Giuseppe, Sbrana, Andrea, Simeone, Ester, Silvestri, Antonia, Spada, Massimiliano, Tarantino, Paolo, Taveggia, Paola, Tomei, Federica, Vincenzo, Tortora, Trapani, Dario, Trojanello, Claudia, Vanella, Vito, Vari, Sabrina, Ventriglia, Jole, Vitale, Maria Grazia, Vitiello, Fabiana, Vivaldi, Caterina, von Arx, Claudia, Zacchi, Francesca, Zampiva, Ilaria, Zivi, Andrea, Daniele, Bruno, Ascierto, Paolo Antonio, Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.
المصدر: Journal for ImmunoTherapy of Cancer
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)مصطلحات موضوعية: Male, Cancer Research, Immune checkpoint inhibitors, Programmed Cell Death 1 Receptor, Practice Patterns, Medical Oncology, B7-H1 Antigen, Antineoplastic Agents, Immunological, 0302 clinical medicine, Drug Prescription, Neoplasms, Surveys and Questionnaires, Pandemic, Prevalence, Surveys and Questionnaire, Infection control, Immunology and Allergy, CTLA-4 Antigen, 030212 general & internal medicine, Viral, Practice Patterns, Physicians', RC254-282, Clinical/Translational Cancer Immunotherapy, Oncologists, Geography, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, antineoplastic protocols, Immunological, Oncology, Italy, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, Coronavirus Infections, Human, healthcare economics and organizations, Adult, Telemedicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Immunology, Antineoplastic Agents, lung neoplasms, Drug Prescriptions, Time-to-Treatment, 03 medical and health sciences, Betacoronavirus, medicine, melanoma, COVID-19, Humans, Infection Control, Pandemics, SARS-CoV-2, Medical prescription, Pharmacology, Physicians', Betacoronaviru, Coronavirus Infection, Cancer, Outbreak, Pneumonia, medicine.disease, lung neoplasm, antineoplastic protocol, Family medicine, healthcare economics and organization, Oncologist, Neoplasm
الوصف: BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.MethodsThis survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options.ResultsThis is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.ConclusionOur study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbec51cbd465b3f335830ebbeec5befTest
http://hdl.handle.net/11568/1114478Test -
9
المؤلفون: Marco Manfrini, Davide Donati, Stefano Lari, R N Cristiana Forni, Roberto Biagini, Patrizia Bacchini, Franco Bertoni, Gaetano Bacci, Gabriella Bernini, Alessandra Longhi, Stefano Ferrari
المساهمون: Bacci G., Bertoni F., Longhi A., Ferrari S., Forni C., Biagini R., Bacchini P., Donati D., Manfrini M., Bernini G., Lari S.
المصدر: Cancer. 97:3068-3075
مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Pathology, Adolescent, Prognosi, medicine.medical_treatment, Preoperative care, Gastroenterology, Internal medicine, Response to chemotherapy, Preoperative Care, medicine, Humans, Antineoplastic Protocol, Neoadjuvant therapy, Survival analysis, Osteosarcoma, Chemotherapy, business.industry, Antineoplastic Protocols, Cancer, Extremities, Prognosis, medicine.disease, Survival Analysis, Neoadjuvant Therapy, Oncology, Chemotherapy, Adjuvant, Localized disease, Female, Histopathology, Survival Analysi, Histologic subtype, business, Human
الوصف: BACKGROUND In primary central high-grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy. METHODS The authors investigated whether the subtypes correlated with histologic response to chemotherapy in 1058 patients with osteosarcoma of the extremities who were treated with neoadjuvant chemotherapy over the last 20 years. The tumors were classified as osteoblastic (70%), chondroblastic (13%), fibroblastic (9%), and telangiectatic (6%). At diagnosis, 911 patients had localized disease and 147 had resectable lung metastases. RESULTS The response to preoperative chemotherapy was good (90% or more tumor necrosis) in 59% of patients and poor (< 90% tumor necrosis) in 41% of patients. The rate of good responses was significantly higher (P = 0.0001) in the fibroblastic (83%) and telangiectatic (80%) tumors and significantly lower in chondroblastic tumors (43%). Prognosis was significantly correlated with the histologic subtypes. The 5-year overall survival rate was significantly higher (P = 0.0001) in fibroblastic (83%) and telangiectatic (75%) tumors than in osteoblastic (62%) and chondroblastic (60%) tumors. In all subtypes, except for the chondroblastic subtype, the 5-year overall survival rate was significantly higher (P = 0.0001) in good responders P = 0.0001 (68%) than in poor responders (52%). CONCLUSIONS The authors concluded that the histologic subtype of primary central high-grade osteosarcoma of the extremity was strictly correlated with histologic response to chemotherapy and probably, as a consequence, also with prognosis. Further studies are needed to establish whether these results justify a specific therapeutic approach based on the histologic subtype of the tumor. Cancer 2003;97:3068–75. © 2003 American Cancer Society. DOI 10.1002/cncr.11456
وصف الملف: STAMPA
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c15fc040be7cd49569faecbe507d4a3dTest
https://doi.org/10.1002/cncr.11456Test -
10دورية أكاديمية
المؤلفون: SOFFIETTI, Riccardo, B. G. Baumert, L. Bello, A. v. Deimling, H. Duffau, M. Frénay, W. Grisold, R. Grant, F. Graus, K. Hoang Xuan, M. Klein, B. Melin, J. Rees, T. Siegal, A. Smits, R. Stupp, W. Wick, E. F. of
المساهمون: R. Soffietti, B. G. Baumert, L. Bello, A. v. Deimling, H. Duffau, M. Frénay, W. Grisold, R. Grant, F. Grau, K. Hoang-Xuan, M. Klein, B. Melin, J. Ree, T. Siegal, A. Smit, R. Stupp, W. Wick, E. F. of
مصطلحات موضوعية: Advisory Committee, trends, Antineoplastic Protocol, standards, Cognition Disorder, drug therapy/etiology/surgery, Combined Modality Therapy, methods/standards, Europe, Evidence-Based Medicine, Glioma, radiotherapy/surgery/therapy, Humans, Neoplasm Metastasi, diagnosis/drug therapy/radiotherapy, Neoplasm Recurrence, Local, drug therapy/radiotherapy/surgery, Neurosurgical Procedure, Prognosis
الوصف: WHO classification recognizes grade II astrocytomas, oligodendrogliomas and oligoastrocytomas. Conventional MRI is used for differential diagnosis, guiding surgery, planning radiotherapy and monitoring treatment response. Advanced imaging techniques can increase the diagnostic accuracy. Younger age, normal neurological examination, oligodendroglial histology and 1p loss are favorable prognostic factors. Prophylactic antiepileptic drugs are not useful, whilst there is no evidence that one drug is better than the others. Total/near total resection can improve seizure control, progression-free and overall survival, whilst reducing the risk of malignant transformation. Early post-operative radiotherapy improves progression-free but not overall survival. Low doses of radiation are as effective as high doses and better tolerated. Modern radiotherapy techniques reduce the risk of late cognitive deficits. Chemotherapy can be useful both at recurrence after radiotherapy and as initial treatment after surgery to delay the risk of late neurotoxicity from large-field radiotherapy. Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments and psychological distress.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/20718851; info:eu-repo/semantics/altIdentifier/wos/WOS:000280996800005; volume:17; firstpage:1124; lastpage:1133; numberofpages:9; journal:EUROPEAN JOURNAL OF NEUROLOGY; http://hdl.handle.net/2318/121624Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-77955817286
